| Year |
Citation |
Score |
| 2024 |
Chatenoud L, Herold KC, Bach JF, Bluestone JA. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives in Medicine. PMID 39284671 DOI: 10.1101/cshperspect.a041600 |
0.303 |
|
| 2024 |
Greenbaum CJ, Nepom GT, Wood-Heickman LK, Wherrett DK, DiMeglio LA, Herold KC, Krischer JP. Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop. Diabetes. PMID 39167668 DOI: 10.2337/dbi24-0020 |
0.447 |
|
| 2024 |
Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley PS, Long SA, Liu C, Koroleva G, Martins AJ, Tsang JS, Herold KC. Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at-risk for type 1 diabetes. The Journal of Clinical Investigation. PMID 39137044 DOI: 10.1172/JCI177492 |
0.395 |
|
| 2024 |
Herold KC, Krischer JP. The Pathogenesis of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. PMID 39134388 DOI: 10.1101/cshperspect.a041623 |
0.328 |
|
| 2024 |
Quandt Z, Perdigoto A, Anderson MS, Herold KC. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harbor Perspectives in Medicine. PMID 39038853 DOI: 10.1101/cshperspect.a041603 |
0.383 |
|
| 2024 |
Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, et al. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care. PMID 38621411 DOI: 10.2337/dc24-0171 |
0.364 |
|
| 2024 |
Abdel-Karim TR, Hodges JS, Herold KC, Pruett TL, Ramanathan KV, Hering BJ, Dunn TB, Kirchner VA, Beilman GJ, Bellin MD. Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International : Official Journal of the European Society For Organ Transplantation. 37: 12320. PMID 38357216 DOI: 10.3389/ti.2024.12320 |
0.304 |
|
| 2024 |
Latres E, Greenbaum CJ, Oyaski ML, Dayan CM, Colhoun HM, Lachin JM, Skyler JS, Rickels MR, Ahmed ST, Dutta S, Herold KC, Marinac M. Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes. PMID 38349844 DOI: 10.2337/dbi23-0012 |
0.358 |
|
| 2024 |
Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK. The immunology of type 1 diabetes. Nature Reviews. Immunology. PMID 38308004 DOI: 10.1038/s41577-023-00985-4 |
0.39 |
|
| 2023 |
Russell WE, Moore DJ, Herold KC. Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013. Diabetes Care. 46: e210-e211. PMID 37890101 DOI: 10.2337/dci23-0050 |
0.346 |
|
| 2023 |
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. The New England Journal of Medicine. PMID 37861217 DOI: 10.1056/NEJMoa2308743 |
0.431 |
|
| 2023 |
Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, ... ... Herold KC, et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care. PMID 37708415 DOI: 10.2337/dc23-1096 |
0.4 |
|
| 2023 |
Sims EK, Geyer SM, Long SA, Herold KC. High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia. PMID 37667106 DOI: 10.1007/s00125-023-06003-5 |
0.401 |
|
| 2023 |
Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care. PMID 37607392 DOI: 10.2337/dc23-0675 |
0.402 |
|
| 2023 |
Delgado AL, Preston-Hurlburt P, Lim N, Sumida TS, Long SA, McNamara J, Serti E, Higdon L, Herold KC. Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. Medrxiv : the Preprint Server For Health Sciences. PMID 37502867 DOI: 10.1101/2023.07.11.23292344 |
0.331 |
|
| 2023 |
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, ... ... Herold KC, et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care. PMID 36920087 DOI: 10.2337/dc22-2200 |
0.467 |
|
| 2023 |
Caulfield JI, Aizenbud L, Perdigoto AL, Meffre E, Jilaveanu L, Michalek DA, Rich SS, Aizenbud Y, Adeniran A, Herold KC, Austin MR, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For Immunotherapy of Cancer. 11. PMID 36898736 DOI: 10.1136/jitc-2022-006570 |
0.367 |
|
| 2023 |
Lu JY, Wilson J, Hou W, Fleysher R, Herold BC, Herold KC, Duong TQ. Incidence of new-onset in-hospital and persistent diabetes in COVID-19 patients: comparison with influenza. Ebiomedicine. 90: 104487. PMID 36857969 DOI: 10.1016/j.ebiom.2023.104487 |
0.317 |
|
| 2023 |
Kinney M, You L, Sims EK, Wherrett D, Schatz D, Lord S, Krischer J, Russell WE, Gottlieb PA, Libman I, Buckner J, DiMeglio LA, Herold KC, Steck AK. Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials. Journal of the Endocrine Society. 7: bvad003. PMID 36741943 DOI: 10.1210/jendso/bvad003 |
0.303 |
|
| 2023 |
Wilson DM, Pietropaolo SL, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck AK, Vasudevan MM, McKay SV, Sherr JL, Herold KC, Dunne JL, Greenbaum CJ, Lord SM, Haller MJ, et al. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care. PMID 36730530 DOI: 10.2337/dc22-1297 |
0.634 |
|
| 2022 |
Sims EK, Cuthbertson D, Felton JL, Ismail HM, Nathan BM, Jacobsen LM, Paprocki E, Pugliese A, Palmer J, Atkinson M, Evans-Molina C, Skyler JS, Redondo MJ, Herold KC, Sosenko JM. Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. Diabetes Care. PMID 36326757 DOI: 10.2337/dc22-1362 |
0.32 |
|
| 2022 |
Anderson RL, DiMeglio LA, Mander AP, Dayan CM, Linsley PS, Herold KC, Marinac M, Ahmed ST. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care. 45: 2189-2201. PMID 36150059 DOI: 10.2337/dc22-0308 |
0.334 |
|
| 2022 |
Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J. The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk. Diabetes Care. PMID 35998266 DOI: 10.2337/dc22-0167 |
0.387 |
|
| 2022 |
Mallone R, Halliez C, Rui J, Herold KC. The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events? Diabetes. 71: 1603-1610. PMID 35881836 DOI: 10.2337/dbi21-0036 |
0.311 |
|
| 2022 |
Yang ML, Horstman S, Gee R, Guyer P, Lam TT, Kanyo J, Perdigoto AL, Speake C, Greenbaum CJ, Callebaut A, Overbergh L, Kibbey RG, Herold KC, James EA, Mamula MJ. Citrullination of glucokinase is linked to autoimmune diabetes. Nature Communications. 13: 1870. PMID 35388005 DOI: 10.1038/s41467-022-29512-0 |
0.449 |
|
| 2021 |
Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, ... ... Herold KC, et al. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. Jci Insight. 6. PMID 34747368 DOI: 10.1172/jci.insight.150074 |
0.366 |
|
| 2021 |
Bluestone JA, Buckner JH, Herold KC. Immunotherapy: Building a bridge to a cure for type 1 diabetes. Science (New York, N.Y.). 373: 510-516. PMID 34326232 DOI: 10.1126/science.abh1654 |
0.394 |
|
| 2021 |
So M, Speake C, Steck AK, Lundgren M, Colman PG, Palmer JP, Herold KC, Greenbaum CJ. Advances in Type 1 Diabetes Prediction using Islet Autoantibodies: Beyond a Simple Count. Endocrine Reviews. PMID 33881515 DOI: 10.1210/endrev/bnab013 |
0.328 |
|
| 2021 |
Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine. 13. PMID 33658358 DOI: 10.1126/scitranslmed.abc8980 |
0.352 |
|
| 2021 |
Lam A, Dayan C, Herold KC. A little help from residual β cells has long-lasting clinical benefits. The Journal of Clinical Investigation. 131. PMID 33529163 DOI: 10.1172/JCI143683 |
0.332 |
|
| 2020 |
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS. Exenatide ER in patients with Type 1 diabetes with and without residual insulin production. Diabetes, Obesity & Metabolism. PMID 32573927 DOI: 10.1111/Dom.14121 |
0.401 |
|
| 2020 |
Sosenko JM, Skyler JS, Herold KC, Schatz DA, Haller MJ, Pugliese A, Cleves M, Geyer S, Rafkin LE, Matheson D, Palmer JP. Slowed Metabolic Decline after One Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 and TrialNet Oral Insulin Prevention Trials. Diabetes. PMID 32439823 DOI: 10.2337/db20-0166 |
0.383 |
|
| 2020 |
Ismail HM, Becker DJ, Libman I, Herold KC, Redondo MJ, Atkinson MA, Cleves MA, Palmer J, Sosenko J. Early and Late C-peptide Responses during Oral Glucose Tolerance Testing are Oppositely Predictive of Type 1 Diabetes in Autoantibody Positive Individuals. Diabetes, Obesity & Metabolism. PMID 32003110 DOI: 10.1111/Dom.13982 |
0.376 |
|
| 2020 |
Herold K. Abstract IA09: Checkpoint inhibitor-induced autoimmune diabetes and endocrine syndromes Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Ia09 |
0.455 |
|
| 2019 |
Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, et al. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. Jci Insight. 4. PMID 31852846 DOI: 10.1172/jci.insight.126054 |
0.313 |
|
| 2019 |
Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, et al. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. PMID 31753960 DOI: 10.2337/Dc19-0880 |
0.409 |
|
| 2019 |
Herold KC, Bundy BN, Krischer JP. Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply. The New England Journal of Medicine. 381: 1880-1881. PMID 31693818 DOI: 10.1056/NEJMc1912500#sa4 |
0.386 |
|
| 2019 |
Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi NB, Lim K, Nahafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang H, Herold K, Harris PE, Sherwin RS, Carson RE, et al. PET Imaging of Pancreatic Dopamine D3/D2 receptor density with C (+)-PHNO in Type-1 Diabetes Mellitus. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31601695 DOI: 10.2967/Jnumed.119.234013 |
0.309 |
|
| 2019 |
Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet (London, England). PMID 31533907 DOI: 10.1016/S0140-6736(19)32127-0 |
0.461 |
|
| 2019 |
Usmani-Brown S, Perdigoto AL, Lavoie N, Clark P, Korah M, Rui J, Betancur G, Herold KC. β cell responses to inflammation. Molecular Metabolism. 27: S104-S113. PMID 31500821 DOI: 10.1016/j.molmet.2019.06.013 |
0.356 |
|
| 2019 |
Simmons KM, Fouts A, Pyle L, Clark P, Dong F, Yu L, Usmani-Brown S, Gottlieb P, Herold KC, Steck AK. Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk of Diabetes. International Journal of Molecular Sciences. 20. PMID 31398795 DOI: 10.3390/Ijms20163857 |
0.402 |
|
| 2019 |
Ahmed S, Cerosaletti K, James E, Long SA, Mannering S, Speake C, Nakayama M, Tree T, Roep BO, Herold KC, Brusko TM. Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances. Diabetes. 68: 1366-1379. PMID 31221801 DOI: 10.2337/Db19-0119 |
0.316 |
|
| 2019 |
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. The New England Journal of Medicine. PMID 31180194 DOI: 10.1056/Nejmoa1902226 |
0.446 |
|
| 2019 |
Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, ... ... Herold KC, et al. Low-dose Anti-Thymocyte Globulin Preserves C-Peptide and Reduces A1c in New Onset Type 1 Diabetes: Two Year Clinical Trial Data. Diabetes. PMID 30967424 DOI: 10.2337/Db19-0057 |
0.374 |
|
| 2019 |
Perdigoto AL, Quandt Z, Anderson M, Herold KC. Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. The Lancet. Diabetes & Endocrinology. PMID 30885563 DOI: 10.1016/S2213-8587(19)30072-5 |
0.349 |
|
| 2019 |
ISMAIL HM, BUNDY BN, ATKINSON MA, MOORE WV, HALLER MJ, RUSSELL WE, GITELMAN SE, HEROLD KC, REDONDO MJ, SOSENKO JM. 1689-P: Assessments of Alternative C-Peptide (C-P) Endpoints for New-Onset Type 1 Diabetes (T1D) Clinical Trials Diabetes. 68: 1689-P. DOI: 10.2337/Db19-1689-P |
0.307 |
|
| 2018 |
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. PMID 30569273 DOI: 10.1007/S00125-018-4786-9 |
0.412 |
|
| 2018 |
Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care. PMID 30305348 DOI: 10.2337/dc18-1465 |
0.335 |
|
| 2018 |
Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, et al. Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. Jci Insight. 3. PMID 30232284 DOI: 10.1172/Jci.Insight.122146 |
0.376 |
|
| 2018 |
Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, et al. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes. Diabetes Care. PMID 30012675 DOI: 10.2337/Dc18-0494 |
0.32 |
|
| 2018 |
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. PMID 29937434 DOI: 10.2337/Dbi18-0002 |
0.364 |
|
| 2018 |
Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ. Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. Genes and Immunity. PMID 29925930 DOI: 10.1038/S41435-018-0032-1 |
0.365 |
|
| 2018 |
Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA. Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes. PMID 29769238 DOI: 10.2337/Db18-0065 |
0.418 |
|
| 2017 |
Gülden E, Palm N, Herold KC. MAIT Cells: A Link between Gut Integrity and Type 1 Diabetes. Cell Metabolism. 26: 813-815. PMID 29211981 DOI: 10.1016/j.cmet.2017.11.007 |
0.367 |
|
| 2017 |
Naushad N, Perdigoto AL, Rui J, Herold KC. Have we pushed the needle for treatment of Type 1 diabetes? Current Opinion in Immunology. 49: 44-50. PMID 28992525 DOI: 10.1016/j.coi.2017.09.004 |
0.376 |
|
| 2017 |
Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, Herold KC, Wen L, Flavell RA. Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. Proceedings of the National Academy of Sciences of the United States of America. PMID 28894001 DOI: 10.1073/Pnas.1705599114 |
0.381 |
|
| 2017 |
Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC. β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice. Cell Metabolism. PMID 28190773 DOI: 10.1016/j.cmet.2017.01.005 |
0.332 |
|
| 2016 |
Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Science Immunology. 1. PMID 28664195 DOI: 10.1126/Sciimmunol.Aai7793 |
0.3 |
|
| 2016 |
Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia. PMID 27704166 DOI: 10.1007/s00125-016-4122-1 |
0.363 |
|
| 2016 |
Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC. The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. Journal of Immunology (Baltimore, Md. : 1950). PMID 27655844 DOI: 10.4049/jimmunol.1600197 |
0.337 |
|
| 2016 |
Garyu JW, Meffre E, Cotsapas C, Herold KC. Progress and challenges for treating Type 1 diabetes. Journal of Autoimmunity. PMID 27210268 DOI: 10.1016/j.jaut.2016.04.004 |
0.319 |
|
| 2016 |
Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC. Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes. Diabetes Care. PMID 27208317 DOI: 10.2337/dc15-2077 |
0.348 |
|
| 2016 |
Garyu JW, Uduman M, Stewart A, Rui J, Deng S, Shenson J, Staron MM, Kaech SM, Kleinstein SH, Herold KC. Characterization of diabetogenic CD8+ T cells: immune therapy with metabolic blockade. The Journal of Biological Chemistry. PMID 26994137 DOI: 10.1074/Jbc.M115.713362 |
0.387 |
|
| 2016 |
Rui J, Deng S, Lebastchi J, Clark PL, Usmani-Brown S, Herold KC. Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice. Diabetologia. PMID 26910463 DOI: 10.1007/s00125-016-3897-4 |
0.331 |
|
| 2015 |
Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine. 7: 315ra189. PMID 26606968 DOI: 10.1126/Scitranslmed.Aad4134 |
0.316 |
|
| 2015 |
Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ. Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. Diabetes Care. 38: 1975-85. PMID 26404927 DOI: 10.2337/Dc15-1429 |
0.358 |
|
| 2015 |
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 38: 1964-74. PMID 26404926 DOI: 10.2337/Dc15-1419 |
0.378 |
|
| 2015 |
Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP. The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. Diabetes Care. 38: 940-2. PMID 25758770 DOI: 10.2337/dc14-2787 |
0.381 |
|
| 2015 |
Reed JC, Herold KC. Thinking bedside at the bench: the NOD mouse model of T1DM. Nature Reviews. Endocrinology. 11: 308-14. PMID 25623120 DOI: 10.1038/nrendo.2014.236 |
0.366 |
|
| 2015 |
Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP. A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care. 38: 271-6. PMID 25519451 DOI: 10.2337/dc14-1813 |
0.343 |
|
| 2014 |
Tooley JE, Herold KC. Biomarkers in type 1 diabetes: application to the clinical trial setting. Current Opinion in Endocrinology, Diabetes, and Obesity. 21: 287-92. PMID 24937037 DOI: 10.1097/MED.0000000000000076 |
0.353 |
|
| 2014 |
Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP. Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care. 37: 979-84. PMID 24550217 DOI: 10.2337/dc13-2359 |
0.306 |
|
| 2014 |
Vudattu NK, Herold KC. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opinion On Biological Therapy. 14: 377-85. PMID 24517093 DOI: 10.1517/14712598.2014.881797 |
0.459 |
|
| 2014 |
Viehmann Milam AA, Maher SE, Gibson JA, Lebastchi J, Wen L, Ruddle NH, Herold KC, Bothwell AL. A humanized mouse model of autoimmune insulitis. Diabetes. 63: 1712-24. PMID 24478396 DOI: 10.2337/Db13-1141 |
0.42 |
|
| 2014 |
Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells. Cell Metabolism. 19: 109-21. PMID 24332968 DOI: 10.1016/J.Cmet.2013.11.007 |
0.315 |
|
| 2014 |
Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC. Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes/Metabolism Research and Reviews. 30: 154-62. PMID 24115337 DOI: 10.1002/Dmrr.2478 |
0.627 |
|
| 2014 |
Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 37: 210-6. PMID 23939544 DOI: 10.2337/Dc13-1169 |
0.613 |
|
| 2014 |
Putnam A, Lares A, Liu W, Lee M, Gitelman S, Herold K, Warner N, Bluestone J. Results following completion of phase I clinical trial using ex vivo expanded CD4+CD127lo/-CD25+ polyclonal tregs for the treatment of recent-onset type 1 diabetes Cytotherapy. 16: S7. DOI: 10.1016/J.Jcyt.2014.01.013 |
0.414 |
|
| 2013 |
Herold KC. Restoring immune balance in type 1 diabetes. The Lancet. Diabetes & Endocrinology. 1: 261-3. PMID 24622404 DOI: 10.1016/S2213-8587(13)70123-2 |
0.392 |
|
| 2013 |
Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes. 62: 4179-83. PMID 23863814 DOI: 10.2337/db13-0656 |
0.393 |
|
| 2013 |
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 62: 3766-74. PMID 23835333 DOI: 10.1089/Dia.2014.1510 |
0.457 |
|
| 2013 |
Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clinical Immunology (Orlando, Fla.). 149: 268-78. PMID 23726024 DOI: 10.1016/j.clim.2013.05.001 |
0.333 |
|
| 2013 |
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (London, England). 381: 1905-15. PMID 23562090 DOI: 10.1016/S0140-6736(13)60023-9 |
0.421 |
|
| 2013 |
Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nature Reviews. Immunology. 13: 243-56. PMID 23524461 DOI: 10.1038/Nri3422 |
0.336 |
|
| 2013 |
Hughes JW, Herold KC. Novel SIRT1 mutation linked to autoimmune diabetes in humans. Cell Metabolism. 17: 311-2. PMID 23473025 DOI: 10.1016/j.cmet.2013.02.014 |
0.308 |
|
| 2013 |
Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni PP, Schneider D, Calvo TR, Coulombe M, Herold K, Gill RG, Atkinson M, et al. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. Plos One. 8: e54712. PMID 23405091 DOI: 10.1371/Journal.Pone.0054712 |
0.448 |
|
| 2013 |
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 56: 391-400. PMID 23086558 DOI: 10.1007/S00125-012-2753-4 |
0.639 |
|
| 2012 |
Lebastchi J, Herold KC. Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harbor Perspectives in Medicine. 2: a007708. PMID 22675665 DOI: 10.1101/cshperspect.a007708 |
0.423 |
|
| 2012 |
Sosenko JM, Skyler JS, Herold KC, Palmer JP. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes. 61: 1331-7. PMID 22618768 DOI: 10.2337/db11-1660 |
0.433 |
|
| 2012 |
Czyzyk J, Henegariu O, Preston-Hurlburt P, Baldzizhar R, Fedorchuk C, Esplugues E, Bottomly K, Gorus FK, Herold K, Flavell RA. Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 188: 6319-27. PMID 22593614 DOI: 10.4049/Jimmunol.1200467 |
0.52 |
|
| 2012 |
Normandin MD, Petersen KF, Ding YS, Lin SF, Naik S, Fowles K, Skovronsky DM, Herold KC, McCarthy TJ, Calle RA, Carson RE, Treadway JL, Cline GW. In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 908-16. PMID 22573821 DOI: 10.2967/Jnumed.111.100545 |
0.307 |
|
| 2012 |
Tooley JE, Waldron-Lynch F, Herold KC. New and future immunomodulatory therapy in type 1 diabetes. Trends in Molecular Medicine. 18: 173-81. PMID 22342807 DOI: 10.1016/j.molmed.2012.01.001 |
0.398 |
|
| 2012 |
Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, Herold KC. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Science Translational Medicine. 4: 118ra12. PMID 22277969 DOI: 10.1126/Scitranslmed.3003401 |
0.317 |
|
| 2012 |
Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop? The notion of homicide or β-cell suicide revisited (Diabetes (2011) 60, (1370-1379)) Diabetes. 61: 1648. DOI: 10.2337/Db12-Er06A |
0.499 |
|
| 2011 |
Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM, Herold KC. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proceedings of the National Academy of Sciences of the United States of America. 108: 19018-23. PMID 22074781 DOI: 10.1073/Pnas.1111008108 |
0.344 |
|
| 2011 |
Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A. Effect of rituximab on human in vivo antibody immune responses. The Journal of Allergy and Clinical Immunology. 128: 1295-1302.e5. PMID 21908031 DOI: 10.1016/J.Jaci.2011.08.008 |
0.347 |
|
| 2011 |
Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Science Translational Medicine. 3: 95fs1. PMID 21832236 DOI: 10.1126/Scitranslmed.3002981 |
0.409 |
|
| 2011 |
Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, Pugliese A, Krischer J, Eisenbarth GS. Rituximab selectively suppresses specific islet antibodies Diabetes. 60: 2560-2565. PMID 21831969 DOI: 10.2337/Db11-0674 |
0.411 |
|
| 2011 |
Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 187: 1998-2005. PMID 21775681 DOI: 10.4049/Jimmunol.1100539 |
0.424 |
|
| 2011 |
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, ... ... Herold KC, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 378: 487-97. PMID 21719095 DOI: 10.1016/S0140-6736(11)60931-8 |
0.388 |
|
| 2011 |
Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (London, England). 378: 319-27. PMID 21714999 DOI: 10.1016/S0140-6736(11)60895-7 |
0.41 |
|
| 2011 |
Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nature Reviews. Drug Discovery. 10: 439-52. PMID 21629294 DOI: 10.1038/nrd3402 |
0.405 |
|
| 2011 |
Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 60: 1370-9. PMID 21525508 DOI: 10.2337/Db10-1797 |
0.332 |
|
| 2010 |
Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Cuthbertson D, Cowie C, Herold K, Eisenbarth G, Palmer JP. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes. 59: 2386-9. PMID 20682683 DOI: 10.2337/Db10-0534 |
0.523 |
|
| 2010 |
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 464: 1293-300. PMID 20432533 DOI: 10.1038/Nature08933 |
0.485 |
|
| 2010 |
Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 32: 488-99. PMID 20412759 DOI: 10.1016/j.immuni.2010.04.002 |
0.408 |
|
| 2010 |
Cernea S, Herold KC. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clinical Immunology (Orlando, Fla.). 134: 121-9. PMID 19837003 DOI: 10.1016/j.clim.2009.09.005 |
0.312 |
|
| 2010 |
Waldron-Lynch F, Herold KC. Non-FcR-binding anti-CD3 monoclonal antibodies for the treatment of type 1 diabetes Drugs of the Future. 35: 833-838. DOI: 10.1358/dof.2010.035.010.1534009 |
0.317 |
|
| 2010 |
Ablamunits V, Opare-Addo L, Henegariu O, Mandrup-Poulsen T, Herold K. Synergy of IL-1 Receptor Antagonist and Anti-CD3 Monoclonal Antibody in Reversal of Diabetes in NOD Mice Clinical Immunology. 135: S31. DOI: 10.1016/J.Clim.2010.03.095 |
0.385 |
|
| 2009 |
Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes/Metabolism Research and Reviews. 25: 694-704. PMID 19771545 DOI: 10.1002/dmrr.1002 |
0.384 |
|
| 2009 |
Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 58: 2588-95. PMID 19675135 DOI: 10.2337/Db09-0249 |
0.364 |
|
| 2009 |
Begum S, Chen W, Herold KC, Papaioannou VE. Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology. 150: 4512-20. PMID 19589867 DOI: 10.1210/en.2009-0287 |
0.409 |
|
| 2009 |
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clinical Immunology (Orlando, Fla.). 132: 166-73. PMID 19443276 DOI: 10.1016/J.Clim.2009.04.007 |
0.351 |
|
| 2009 |
Waldron-Lynch F, Herold KC. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinology and Metabolism Clinics of North America. 38: 303-17, viii. PMID 19328413 DOI: 10.1016/j.ecl.2009.01.005 |
0.306 |
|
| 2009 |
Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes/Metabolism Research and Reviews. 25: 302-6. PMID 19319985 DOI: 10.1002/Dmrr.933 |
0.418 |
|
| 2008 |
Waldron-Lynch F, von Herrath M, Herold KC. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Foundation Symposium. 292: 146-55; discussion 1. PMID 19203097 |
0.37 |
|
| 2008 |
Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 57: 2883-8. PMID 18971435 DOI: 10.2337/Db07-1817 |
0.37 |
|
| 2008 |
Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Annals of the New York Academy of Sciences. 1126: 7-13. PMID 18448789 DOI: 10.1196/Annals.1433.056 |
0.355 |
|
| 2008 |
Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nature Clinical Practice. Endocrinology & Metabolism. 4: 334-43. PMID 18446141 DOI: 10.1038/Ncpendmet0832 |
0.639 |
|
| 2007 |
Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response Current Molecular Medicine. 7: 743-751. PMID 18331232 DOI: 10.2174/156652407783220714 |
0.313 |
|
| 2007 |
Moser B, Desai DD, Downie MP, Chen Y, Shi FY, Herold K, Schmidt AM, Clynes R. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo Journal of Immunology. 179: 8051-8058. PMID 18056345 DOI: 10.4049/Jimmunol.179.12.8051 |
0.304 |
|
| 2007 |
Von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nature Reviews Immunology. 7: 988-994. PMID 17982429 DOI: 10.1038/Nri2192 |
0.467 |
|
| 2007 |
Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 148: 5136-44. PMID 17673522 DOI: 10.1210/En.2007-0358 |
0.38 |
|
| 2007 |
Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 30: 38-42. PMID 17192330 DOI: 10.2337/dc06-1615 |
0.378 |
|
| 2007 |
Witkowski P, Herold KC. Islet transplantation for type 1 diabetes - Where should we go? Nature Clinical Practice Endocrinology and Metabolism. 3: 2-3. PMID 17179921 DOI: 10.1038/ncpendmet0369 |
0.36 |
|
| 2006 |
Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AMB, Herold KC. Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes Diabetes. 55: 3238-3245. PMID 17130466 DOI: 10.2337/db05-1034 |
0.326 |
|
| 2006 |
Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, Kilbourn M, Jurewicz A, Herold K, Liu E, Hardy MA, Van Heertum R, Harris PE. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nuclear Medicine and Biology. 33: 855-64. PMID 17045165 DOI: 10.1016/J.Nucmedbio.2006.07.002 |
0.452 |
|
| 2006 |
Yan SF, Yan SD, Herold K, Ramsamy R, Schmidt AM. Receptor for Advanced Glycation End Products and the Cardiovascular Complications of Diabetes and Beyond: Lessons from AGEing Endocrinology and Metabolism Clinics of North America. 35: 511-524. PMID 16959583 DOI: 10.1016/J.Ecl.2006.06.003 |
0.488 |
|
| 2006 |
Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: Results of a blinded controlled study Diabetes. 55: 2588-2594. PMID 16936208 DOI: 10.2337/Db05-1378 |
0.391 |
|
| 2006 |
Cernea S, Herold KC. Drug insight: New immunomodulatory therapies in type 1 diabetes. Nature Clinical Practice. Endocrinology & Metabolism. 2: 89-98. PMID 16932263 DOI: 10.1038/ncpendmet0082 |
0.379 |
|
| 2006 |
Cernea S, Herold KC. Drug insight: New immunomodulatory therapies in type 1 diabetes. Nature Clinical Practice. Endocrinology & Metabolism. 2: 89-98. PMID 16932263 DOI: 10.1038/ncpendmet0082 |
0.379 |
|
| 2006 |
Yan SF, Naka Y, Hudson BI, Herold K, Yan SD, Ramasamy R, Schmidt AM. The ligand/RAGE axis: Lighting the fuse and igniting vascular stress Current Atherosclerosis Reports. 8: 232-239. PMID 16640960 DOI: 10.1007/S11883-006-0078-9 |
0.345 |
|
| 2006 |
Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, Von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recentonset autoimmune diabetes by inducing Tregs Journal of Clinical Investigation. 116: 1371-1381. PMID 16628253 DOI: 10.1172/Jci27191 |
0.416 |
|
| 2006 |
Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 29: 643-9. PMID 16505520 DOI: 10.2337/DIACARE.29.03.06.DC05-1006 |
0.418 |
|
| 2006 |
Ouziel-Yahalom L, Zalzman M, Anker-Kitai L, Knoller S, Bar Y, Glandt M, Herold K, Efrat S. Expansion and redifferentiation of adult human pancreatic islet cells Biochemical and Biophysical Research Communications. 341: 291-298. PMID 16446152 DOI: 10.1016/J.Bbrc.2005.12.187 |
0.35 |
|
| 2006 |
Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus Diabetologia. 49: 261-270. PMID 16404554 DOI: 10.1007/s00125-005-0100-8 |
0.44 |
|
| 2006 |
Chen W, Bluestone JA, Herold KC. Achieving antigen-specific tolerance in diabetes: regulating specifically. International Reviews of Immunology. 24: 287-305. PMID 16318983 DOI: 10.1080/08830180500379671 |
0.337 |
|
| 2005 |
Sherry NA, Tsai EB, Herold KC. Natural history of β-cell function in type 1 diabetes Diabetes. 54: S32-S39. PMID 16306337 DOI: 10.2337/diabetes.54.suppl_2.S32 |
0.42 |
|
| 2005 |
Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, et al. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Annals of the New York Academy of Sciences. 1043: 553-61. PMID 16037278 DOI: 10.1196/Annals.1338.063 |
0.497 |
|
| 2005 |
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 54: 1763-9. PMID 15919798 DOI: 10.2337/Diabetes.54.6.1763 |
0.376 |
|
| 2005 |
Bisikirska BC, Herold KC. Regulatory T cells and type 1 diabetes. Current Diabetes Reports. 5: 104-9. PMID 15794912 DOI: 10.1007/S11892-005-0036-X |
0.328 |
|
| 2005 |
Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 15: 16R-28R. PMID 15764591 DOI: 10.1093/Glycob/Cwi053 |
0.351 |
|
| 2005 |
Bisikirska BC, Herold KC. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Annals of the New York Academy of Sciences. 1037: 1-9. PMID 15699486 DOI: 10.1196/ANNALS.1337.001 |
0.368 |
|
| 2005 |
Siegel-Czarkowski L, Herold KC, Goland RS. Continuous subcutaneous insulin infusion in older patients with type 1 diabetes. Diabetes Care. 27: 3022-3. PMID 15562235 DOI: 10.2337/DIACARE.27.12.3022 |
0.396 |
|
| 2004 |
Glandt M, Herold KC. Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation. Current Diabetes Reports. 4: 291-7. PMID 15265472 DOI: 10.1007/S11892-004-0081-X |
0.314 |
|
| 2004 |
Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, Stern D, Herold KC. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. Journal of Immunology (Baltimore, Md. : 1950). 173: 1399-405. PMID 15240736 DOI: 10.4049/Jimmunol.173.2.1399 |
0.424 |
|
| 2004 |
Maffei A, Liu Z, Witkowski P, Moschella F, Del Pozzo G, Liu E, Herold K, Winchester RJ, Hardy MA, Harris PE. Identification of tissue-restricted transcripts in human islets. Endocrinology. 145: 4513-21. PMID 15231694 DOI: 10.1210/En.2004-0691 |
0.331 |
|
| 2004 |
Herold KC. Treatment of type 1 diabetes mellitus to preserve insulin secretion. Endocrinology and Metabolism Clinics of North America. 33: 93-111, ix. PMID 15053897 DOI: 10.1016/J.ECL.2004.01.002 |
0.425 |
|
| 2004 |
Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes. 53: 426-33. PMID 14747294 DOI: 10.2337/Diabetes.53.2.426 |
0.384 |
|
| 2004 |
Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 53: 250-64. PMID 14693724 DOI: 10.2337/Diabetes.53.1.250 |
0.444 |
|
| 2004 |
Glandt M, Hagopian W, Herold KC. Treatment of type 1 diabetes with anti-CD3 monoclonal antibody. Reviews in Endocrine & Metabolic Disorders. 4: 361-8. PMID 14618021 DOI: 10.1023/A:1027354129493 |
0.328 |
|
| 2002 |
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. The New England Journal of Medicine. 346: 1692-8. PMID 12037148 DOI: 10.1056/Nejmoa012864 |
0.432 |
|
| 2002 |
Cook S, Herold K, Edidin DV, Briars R. Increasing problem solving in adolescents with type 1 diabetes: the choices diabetes program. The Diabetes Educator. 28: 115-24. PMID 11852741 DOI: 10.1177/014572170202800113 |
0.453 |
|
| 2001 |
Efrat S, Serreze D, Svetlanov A, Post CM, Johnson EA, Herold K, Horwitz M. Adenovirus early region 3(E3) immunomodulatory genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes. 50: 980-984. PMID 11334441 DOI: 10.2337/Diabetes.50.5.980 |
0.451 |
|
| 1997 |
Herold KC, Baumann E, Vezys V, Buckingham F. Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H-2d mice. Journal of Autoimmunity. 10: 17-25. PMID 9080296 DOI: 10.1006/Jaut.1996.0108 |
0.34 |
|
| 1996 |
O'Meara NM, Sturis J, Herold KC, Ostrega DM, Polonsky KS. Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care. 18: 568-71. PMID 7497873 DOI: 10.2337/Diacare.18.4.568 |
0.366 |
|
| 1995 |
Herold KC, Bloch TN, Vezys V, Sun Q. Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells. Diabetes. 44: 354-9. PMID 7883124 DOI: 10.2337/diab.44.3.354 |
0.311 |
|
| 1995 |
Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. The Journal of Experimental Medicine. 181: 1145-55. PMID 7532678 DOI: 10.1084/Jem.181.3.1145 |
0.396 |
|
| 1995 |
Herold KC, Bloch TN, Vezys V, Sun Q. Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells Diabetes. 44: 354-359. DOI: 10.2337/diabetes.44.3.354 |
0.303 |
|
| 1994 |
Herold KC, Vezys V, Gage A, Montag AG. Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cellular Immunology. 157: 489-500. PMID 7915204 DOI: 10.1006/cimm.1994.1244 |
0.391 |
|
| 1992 |
Herold KC, Rubenstein AH. New directions in the immunology of autoimmune diabetes Annals of Internal Medicine. 117: 436-438. PMID 1503336 DOI: 10.7326/0003-4819-117-5-436 |
0.404 |
|
| 1992 |
Herold KC, Montag AG, Buckingham F. Induction of tolerance to autoimmune diabetes with islet antigens. The Journal of Experimental Medicine. 176: 1107-14. PMID 1402656 DOI: 10.1084/jem.176.4.1107 |
0.306 |
|
| 1991 |
Herold KC, Kastern W, Markholst H, Lernmark A. Derivation of non-lymphopenic BB rats with an intercross breeding. Autoimmunity. 3: 83-93. PMID 2577492 DOI: 10.3109/08916938909019957 |
0.408 |
|
| 1988 |
Herold KC, Rubenstein AH. Immunosuppression for insulin-dependent diabetes New England Journal of Medicine. 318: 701-703. PMID 3344022 DOI: 10.1056/NEJM198803173181110 |
0.399 |
|
| 1986 |
Jaspan JB, Towle VL, Maselli R, Herold K. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism: Clinical and Experimental. 35: 83-92. PMID 3083212 DOI: 10.1016/0026-0495(86)90193-9 |
0.357 |
|
| 1985 |
Jaspan JB, Herold K, Bartkus C. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. The American Journal of Medicine. 79: 24-37. PMID 3000176 DOI: 10.1016/0002-9343(85)90507-8 |
0.377 |
|
| 1984 |
Polonsky KS, Herold KC, Gilden JL, Bergenstal RM, Fang VS, Moossa AR, Jaspan JB. Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes. 33: 1112-9. PMID 6389228 DOI: 10.2337/Diab.33.11.1112 |
0.38 |
|
| 1984 |
Herold KC, Huen A, Gould L, Traisman H, Rubenstein AH. Alterations in lymphocyte subpopulations in type 1 (insulin-dependent) diabetes mellitus: exploration of possible mechanisms and relationships to autoimmune phenomena Diabetologia. 27: 102-105. PMID 6237011 DOI: 10.1007/BF00275660 |
0.444 |
|
| 1983 |
Jaspan J, Maselli R, Herold K, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet (London, England). 2: 758-62. PMID 6137601 DOI: 10.1016/S0140-6736(83)92296-1 |
0.354 |
|
| Show low-probability matches. |